RSS   Newsletter   Contact   Advertise with us
Post Online Media

ARMO BioSciences appoints Joseph Leveque as CMO

ARMO BioSciencesOctober 10, 2017, Redwood City, Ca., USA - ARMO BioSciences, a late-stage immuno-oncology company, announced the appointment of Joseph Leveque as chief medical officer.
Dr. Leveque has more than 20 years of experience in the biopharmaceutical industry leading teams in the successful development and commercialization of oncology therapeutics.

Dr. Leveque was the Chief Medical Officer of EMD Serono, the North America subsidiary of Merck KGaA and the Vice President and Head of U.S. Medical Oncology at Bristol-Myers Squibb (BMS) where he was involved in the development and commercialization of the first generation of immuno-oncology (IO) therapeutics, including Bavencio, Opdivo and Yervoy.

Prior to BMS, Dr. Leveque was the Vice President of Medical and Scientific Affairs at Onyx Pharmaceuticals, where he was involved in the development of Kyprolis and was recognized by the Multiple Myeloma Research Foundation as one of the top 15 innovators in multiple myeloma over the last 15 years.

Earlier in his career, he served as Vice President of Medical and Scientific Affairs at Cephalon Oncology and a Medical Director at Amgen, where he worked on several therapeutic programs for solid tumor and hematological malignancies.

Dr. Leveque received a Bachelor of Arts and Sciences with an emphasis in biology from the Santa Clara University.

He earned a Medical Doctorate from University of Texas School of Medicine in Houston and completed his post-graduate medical training in internal medicine at the Cedars-Sinai Medical Center, a teaching affiliate of UCLA.

In addition, Dr. Leveque holds a Master in Business Administration from the Wharton School of the University of Pennsylvania.




POST Online Media does not use cookies to collect information about visitors.   OK, hide this message   Third party ads may be using cookies, you can see how here.